Squarepoint
FULC icon

Squarepoint’s Fulcrum Therapeutics FULC Stock Holding History

Squarepoint’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-57,900
Closed -$272K – 4865
2024
Q4 		$272K Hold
57,900
– – ﹤0.01% 4227
2024
Q3 		$207K Sell
57,900
-63,600
-52% -$472K ﹤0.01% 3670
2024
Q2 		$753K Buy
121,500
+101,400
+504% +$768K ﹤0.01% 2764
2024
Q1 		$190K Buy
+20,100
New +$179K ﹤0.01% 3629

Other funds holding FULC

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
FTM
First Turn Management Del Mar, California $895M AUM 261.28% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

Squarepoint's FULC Position: Q1 2026 in Review

Squarepoint increased its Fulcrum Therapeutics (FULC) stake by 167% in Q1 2026, buying an estimated $1.02M and bringing the position to 175,944 shares worth $1.35M. The position accounts for ﹤0.01% of the portfolio, ranked #2514.

Squarepoint first reported a position in FULC in Q1 2020 and has held it in 14 quarters since. 169 funds tracked by Wall St. Rank hold FULC as of Q1 2026.

  • Squarepoint held 175,944 shares of Fulcrum Therapeutics worth $1.35M as of Q1 2026.
  • Squarepoint bought 110,092 Fulcrum Therapeutics shares in Q1 2026, an estimated $1.02M.
  • Fulcrum Therapeutics made up ﹤0.01% of Squarepoint's portfolio in Q1 2026, its #2514 holding.
  • Squarepoint first reported a position in Fulcrum Therapeutics in Q1 2020 and has held it in 14 quarters since.
  • 169 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q1 2026.

Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.